Company: TLSA
Filing Date: 2025-03-25
Form Type: 6-K
Source: 0001013762-25-001845
Chunk: 0

Company: Tiziana Life Sciences Ltd
Filing Date: 2025-03-25
Form: 6-K
Chunk 0
---
<div align='center'>UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

March 2025

Commission File Number: 001-38723

Tiziana Life Sciences LTD

(Exact Name of Registrant as Specified in Its Charter)

9 thFloor

107 Cheapside

London

EC2V 6DN

(Address of registrant’s principal executive
office)</div>

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

<div align='center'>Form 20-F ☒ Form 40-F ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K</div>

On March 25, 2025, Tiziana Life Sciences LTD (the “”)
issued this 6K announcing, dosing of new patients at Yale MS Center which is participating in our multicenter Phase 2 clinical trial evaluating
intranasal foralumab for non-active Secondary Progressive Multiple Sclerosis (na-SPMS). Other centers are currently enrolling include
Johns Hopkins, U Mass Medical Center and Brigham and Women’s Hospital. This Phase 2 trial aims to assess the safety, tolerability,
and foralumab’s effect on microglial activation in patients with na-SPMS. Intranasal foralumab offers a novel approach to potentially
mitigate the progression of SPMS. This multicenter study is important because it combines brain PET imaging, immunology, and measures
of clinical evidence accepted by FDA.,a copy of which is furnished as Exhibit 99.1

The Announcement is furnished herewith as Exhibit
99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed “filed”
for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, nor
shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Securities
Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly set forth by specific reference in